-+ 0.00%
-+ 0.00%
-+ 0.00%

GC Biopharma Revises Brazil Supply Contract Value to KRW 142.12 Billion

PUBT·11/02/2026 01:37:59
Listen to the news
GC Biopharma Revises Brazil Supply Contract Value to KRW 142.12 Billion
  • GC Biopharma raised its Brazilian supply contract with BLAU Farmaceutica to KRW 142.12 billion from KRW 121.96 billion in a November 2 correction.
  • The revised amount includes finalized 2026 sales and estimated first-quarter 2027 supplies, representing 8.3% of 2022 consolidated revenue.
  • Supply volumes from the second quarter of 2027 through the contract’s June 29, 2028 expiration remain unconfirmed.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. GC Biopharma Corp. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261102800281), on November 02, 2026, and is solely responsible for the information contained therein.